Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Unresectable Colorectal Cancer 1Solid Tumor 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Hematologic Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11venetoclax 9Azacitidine 9Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × magrolimab × Clear all
NCT03248479 2025-01-17

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Gilead Sciences

Phase 1 Terminated
258 enrolled 38 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡